Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02623972Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in inflammatory breast cancer (IBC), sponsored by Dana-Farber Cancer Institute. Started Feb 2016; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT02623972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623972.